Published: October 5, 2026
StartupFeed Quick Take
- Aignosis raised Rs 4 crore in a seed round co-led by Antler and Nikhil Kamath.
- Its webcam tool screens children aged 16 months to 9 years and runs in 20+ government clinics in Rajasthan.
- The startup wants to hit 100,000 screenings by the end of FY27, up from 8,000 so far.
Jaipur health-tech startup Aignosis has raised Rs 4 crore in a seed round co-led by Nikhil Kamath and the early-stage firm Antler, with angels Varun Dua and IIMA Ventures joining.
The round builds on the company’s first cheque in 2024, which came from angels including Rajneesh Bhandari and Amit Jain. A funding statement from the company confirmed the new investors and the amount.
Aignosis screens young children for autism and other developmental delays. The tool runs on a normal laptop with a webcam. It does not diagnose autism.
The child watches a short video of nine segments. Computer vision then reads signals like where the child looks, how they answer to their name, and how they react to faces. The software returns a risk report flagging who may need a full clinical check.
The founders are Raksheet Jain and Divyansh Mangal. The startup has cleared India’s CDSCO process and holds a Class B certificate for the technology. Google also picked it for the 2025 Google for Startups Accelerator, one of 20 firms chosen from more than 1,600 applicants.
Distribution is the real bet here. Aignosis sells through paediatricians, not as a standalone device, in a model it calls clinic-in-clinic. It is live in more than 20 government primary health centres in Rajasthan.
Reach widens through two partners. Mankind Pharma’s medical representatives, a field force of nearly 1,300 people, help run screening camps. Aignosis is also starting with Apollo Shines, the Apollo group’s school infirmary arm, across about 125 schools.
Kamath said the focus on small clinics is what drew him in. He runs the investment firm Gruhas and hosts the “WTF is” podcast.
“Aignosis is going the other way, starting in government health centres and small clinics, not private hospitals in metros. That’s distribution thinking that actually moves the needle at scale.”
Nikhil Kamath, co-founder, Zerodha. From the Aignosis funding statement, October 2026.
Investors have backed the company before. On Shark Tank India, Aignosis took Rs 1 crore for 8% equity from Peyush Bansal, Aman Gupta and Varun Dua. Its screening is priced near Rs 700 a test.
There is a real gap to fill. Many Indian children are flagged for autism late, well past the age when early help works best, and specialists are scarce outside big cities. Aignosis has run more than 8,000 screenings so far.
Next come seven more states. The company plans to enter Punjab, the Delhi NCR, Haryana, Tamil Nadu, Jharkhand, Karnataka and Maharashtra.
What this means for you: If you run a health-tech startup selling to government clinics, Aignosis is a live test of that route. Watch whether it clears 100,000 screenings by March 2027 before you price your own public-health pilot.
Have a tip? Write to us at editorial@startupfeed.in.
Liked this story? Follow StartupFeed on Google so our reporting reaches you first.
